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Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disorder. The study of diverse mouse models of lupus has
provided clues to the etiology of SLE. Spontaneous mouse models of lupus have led to identiﬁcation of numerous susceptibility
loci from which several candidate genes have emerged. Meanwhile, induced models of lupus have provided insight into the role
of environmental factors in lupus pathogenesis as well as provided a better understanding of cellular mechanisms involved in the
onset and progression of disease. The SLE-like phenotypes present in these models have also served to screen numerous potential
SLEtherapies.DuetothecomplexnatureofSLE,itisnecessarytounderstandtheeﬀect speciﬁctargeted therapieshaveonimmune
homeostasis.Furthermore, knowledge gained from mouse models will provide novel therapy targets for the treatment of SLE.
1.Introduction
The etiology of the autoimmune disease systemic lupus
erythematosus (SLE) is considered to be a combination of
multiple genetic and environmental factors whose amalga-
mation breaches the threshold of immune tolerance. SLE
is, therefore, a complex multigenic disorder. The causative
geneticfactorsofsuchdisordersarebelievedtobeallelicvari-
ants with minor functional contributions to the disease state
and, individually, are not suﬃcient to cause overt disease.
However, the combination of several of these susceptibility
loci can lead to epistatic interactions that greatly enhance the
overallcontributionbyeach locus,whereby protectivemech-
anisms are overcome and pathogenesis ensues. Hence, the
capacity to tailor SLE treatments could be greatly enhanced
upon the identiﬁcation of the genetic variants capable of
inducing autoimmunity and how their involvement can
magnify SLE.Indeed, concertedeﬀortsinhumanstudiesand
mouse models have been made in that direction. The recent
annotation of millions of single nucleotide polymorphisms
(SNPs) in the human genome and the inception of high-
throughput genotyping technologies has enabled the use of
genome-wide association studies (GWAS) for this purpose.
To date, SLE susceptibility has been associated to dozens of
genesby GWAS[1]. While these associations oﬀerimportant
new insights into SLE etiology, there are logistical limitations
to GWAS. Extremely large sample sets are required to
achieve signiﬁcant associations and extrinsic factors such as
ethnicity, clinical history, and lifestyle must be considered in
choosing thesesets.Further,GWASarecapableofidentifying
genomic associations but do not characterize the function
that an allelic variation confers. For this, other methods are
required.
There are numerous murine models that have long
been employed in an eﬀort to understand the cellular and
genetic requirements for SLE induction. The classic models
ofspontaneouslupusincludetheF1hybrid betweentheNew
ZealandBlack(NZB)andNewZealandWhite(NZW)strains
(NZB/WF1) and its derivatives, the MRL/lpr,a n dB X S B / Yaa
strainswhereasinducedmodelsincludethepristane-induced
model and the chronic graft-versus-host-disease models
(cGVHD).Allofthesemodelsportraytheirowniterationsof
lupus-like diseases with a subset of symptoms akin to those
observed in human SLE, namely, autoantibody production,
lymphoid activation and hyperplasia, and lupusnephritis. In
addition to spontaneous and induced lupus models, there
is a plethora of genetically modiﬁed mouse models that
goes beyond the scope of this paper (reviewed in [2]).
Undoubtedly,geneticallymodiﬁed modelswill beusedinthe
characterization of genes identiﬁed by GWAS, and in fact,
many of these models already exist [3]. Here, we focus on
whathasbeenlearnedfromspontaneousandinducedmouse2 Journal of Biomedicine and Biotechnology
models of SLE and how they can be used to complement
the recent advances in human studies. We also highlight how
murine models have been used as tools to test therapies.
2.ClassicMouse ModelsofSpontaneousLupus
2.1. NZB/W F1. The NZB/W F1 is the oldest classical model
of lupus generated by the F1 hybrid between the NZB
and NZW strains. Both NZB and NZW display limited
autoimmunity, while NZB/W F1 hybrids develop severe
lupus-like phenotypes comparable to that of lupus patients
[4]. These lupus-like phenotypes include lymphadenopathy,
splenomegaly, elevated serum antinuclear autoantibodies
(ANA) including anti-dsDNA IgG, a majority of which are
IgG2a and IgG3, and immune complex-mediated glomeru-
lonephritis (GN) that becomes apparent at 5-6 months of
age, leading to kidney failure and death at 10–12 months of
age [4]. Unlike SLE patients and the MRL/lpr and BXSB/Yaa
mouse models, NZB/W F1 mice lack autoantibodies against
RNA-containing complexes. As for SLE patients, disease in
the NZB/W F1 strain is strongly biased in favor of females,
and this is at least in part due to estrogen levels. Indeed
ovariectomy of NZB/W F1 mice not only delayed disease
onset but also decreased autoantibody titer. Meanwhile,
restoration of estradiol in ovariectomized NZB/W F1 mice
reestablished high numbers of DNA-speciﬁc B cells, and
thereby suggests a pathogenic role of estrogen in lupus [5].
The many contributions of the NZB/W F1 model to our
understanding of lupus pathogenesis have been discussed in
excellent reviews [2, 4] to which the reader is referred to.
2.1.1. NZM. An accidental backcross between NZB/W F1
and NZW followed by brother-sister matings generated 27
diﬀerent recombinant inbred strains of New Zealand Mixed
(NZM) mice among which NZM2328 and NZM2410 are
now used as lupus models [6–8]. While both NZM2410
and NZM2328 strains exhibit a highly penetrant version
of the NZB/W F1 disease with an earlier onset, NZM2410
diﬀers from NZM2328 with a weaker gender bias [7]. The
NZM2328 and 2410 strains share the same autoantibody
speciﬁcities as NZB/W F1 mice. The homozygosity of the
NZM strains and their potential enrichment for lupus sus-
ceptibility loci has facilitated genetic analyses, and arguably
their greatest contribution has been to the understanding of
the genetic basis of this disease.
2.1.2. Identiﬁcation and Classiﬁcation of Susceptibility Loci.
In 1994, Morel et al. reported the ﬁrst lupus linkage analysis
which identiﬁed three NZM2410 susceptibility loci, Sle1-
3, as being signiﬁcantly correlated with GN development
[7]. The analysis of these loci showed that disease was
inherited as a threshold liability, that is, the probability
of presenting disease by an individual increases with the
number of susceptibility alleles it carries, a concept that has
been conﬁrmed in genetic analyses of the other lupus-prone
strains. The NZM2410 model was also used to show the
existenceofNZW-derivedsuppressiveloci,thestrongestone,
Sles1, being linked to the major histocompatibility complex
(MHC) class II locus H-2z [9]. These results showed that
the disease outcome for a given genome represents the
integrationofsusceptibilityandresistancelociandthatlupus
susceptible strains carry genomes in which the susceptibility
locioutweightheresistanceloci.Resistance(ortransgressive)
loci have subsequently been identiﬁed in other models,
includinglupusmodels (e.g.,see below Lmb3 in theMRL/lpr
strain).
The phenotypes contributed by each NZM2410 suscep-
tibility locus have been determined via detailed analysis of
the immunological properties of congenic strains carrying
the individual loci on a C57BL/6 (B6) genetic background
in comparison to B6 mice [10–16]. Brieﬂy, Sle1 mediates
the loss of tolerance to nuclear antigens leading to the
production of autoreactive B and T cells culminating in
the secretion of antinuclear autoantibodies. Sle2 leads to B
cell hyperactivity, elevated B-1 cell levels, and polyreactive
IgM antibodies. Sle3 leads to decreased levels of activation-
induced cell death in CD4+ T cells, with evidence that a
non-T cell compartment is involved in the expression of
this phenotype [15]. Interestingly, Sle1 largely overlaps with
NZM2328Cgnz1 and Agnz1 on chromosome 1 and Sle2 with
NZM2328 Adaz1 on chromosome 4 [17]. The NZM2328
loci were, however, evaluated in congenic strains in which
the susceptibilityintervals were replaced by nonautoimmune
genomic segments, which makes impossible to directly
compare the phenotypes of the respective susceptibility loci
between the two strains.
As predicted by the threshold liability ﬁndings from
the linkage analysis, none of the NZM2410-derived Sle
loci lead to full disease presentation. Instead, the stepwise
combination of each congenic interval showed that the
coexpression of these three major loci is necessary and
suﬃcient for the development of fully penetrant disease
[18]. The NZM2410 strain is to date the only autoimmune
model in which the subset of loci that are necessary and
suﬃcient for disease presentation has been identiﬁed. This
achievement infused added signiﬁcance to the identiﬁcation
of the genes corresponding to those three loci. A major
obstacle towards the identiﬁcation of these susceptibility
genes has been revealed by the studies of the Sle congenic
strains, which revealed that the original quantitative trait
loci (QTLs) correspond to a cluster of susceptibility loci.
This ﬁnding has been best demonstrated for Sle1,w h i c h
is reviewed in detail in [3], corresponds to at least seven
independent loci.
2.1.3. Identiﬁcation of NZM2410 Susceptibility Genes.
Progress towards the identiﬁcation of lupus-susceptibility
genes is ongoing in several models (see below), but it is
by far the most advanced in NZM2410 as reviewed in [3].
Most of the genetic variants identiﬁed in these susceptibility
genes are still in the process of formal validation, and the
process by which they contribute to lupus pathogenesis
is still largely unknown. However, variations in many
of these genes has been directly associated with human
lupus, which is by itself a strong validation of the mouse
ﬁndings. The NZM2140 allele of Fcgr2b, which encodes for
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autoimmune phenotype [19] and a large number of studies
have established an association between FCGR2B variants
and human SLE [20]. Consequently, the involvement of
Fcgr2b in lupuspathogenesis has been validated in both mice
and humans at the genetic and functional levels. Similarly,
polymorphisms in Cr2, which encodes the complement
receptor type 2 that acts as a B-cell coreceptor, contribute to
the Sle1c1 phenotypes [21, 22]. A common CR2 haplotype
is more frequent in SLE patients than in healthy controls,
and novel CR2 splice variants are expressed on the follicular
dendritic cells of SLE patients [23, 24]. Sle1b corresponds
to polymorphisms in four signaling lymphocytic activation
molecule (SLAM) family member genes [25], including
Ly108, which was directly implicated in the regulation
of B-cell tolerance [26]. Variants of SLAMF3 (LY9)a n d
SLAMF4 (CD244) have been associated with human SLE
[27, 28]. Finally for the Sle1 subloci, Sle1a1 corresponds to
the expression of a novel splice isoform of the Pbx1 gene that
is associated with increased CD4+ Tc e l la c t i v a t i o ni nb o t h
mice and humans (Cuda et al., in revision). Pbx1 function in
T cells is unknown, and studies are ongoing to uncover the
mechanisms linking Pbx1 expression and T cell phenotypes.
The Sle3 locus induces a complex phenotype that includes
myeloid cell-induced CD4+ T-cell activation [29]a n dm i l d
GN [12] .P o l y m o r p h i s m si nk a l l i k r e i n( Klk) genes, which
are located in the Sle3 interval, have been associated with
increased susceptibility to nephritis in the mouse and in SLE
patients [30].
2.2. MRL/lpr
2.2.1. Derivation and Phenotype of the MRL/lpr Strain.
The MRL strain was developed from several crosses of
inbred strains. Speciﬁcally, most of the MRL genome was
derived from the LG/J strain with minor contributions from
C3H/Di, C57BL/6, and AKR/J [4]. Initial characterization
of MRL substrains revealed one strain, termed MRL/lpr,
which developed an SLE-like phenotype characterized by
lymphadenopathy due to an accumulation of double nega-
tive (CD4− CD8−) and B220+ T-cells. These mice displayed
an accelerated mortality rate, and unlike the NZB/W F1
mice, both males and females were signiﬁcantly aﬀected. In
addition, the MRL/lpr substrain had high concentrations of
circulating immunoglobulins, which included elevated levels
of autoantibodies such as ANA, anti-ssDNA, anti-dsDNA,
anti-Sm, and rheumatoid factors, resulting in large amounts
of immune complexes [31]. This accelerated phenotype
was attributed to a recessive autosomal mutation termed
lymphoproliferation (lpr). The lpr mutation, located on
chromosome 19, alters transcription of the Fas receptor [32].
2.2.2. Eﬀect of Fas Signaling Deﬁciency in Disease Devel-
opment. Fas is a surface-bound receptor belonging to the
tumor necrosis factor receptor (TNF-R) family that induces
apoptosis upon interacting with its ligand, FasL [33]. The
defects in Fas transcription are caused by an insertion of the
retrotransposon ETn which leads to aberrant, nonfunctional
transcripts due to alternative splicing of the Fas gene [34].
Studies on B-cells and T-cells from MRL/lpr mice, which
both express Fas, conﬁrmed a defect in apoptosis due to the
lackoffunctionalFasreceptor[35].Furthermore,amutation
on the FasL gene, termed generalized lymphoproliferative
disease (gld), was shown to cause an autoimmune disorder
similar to the lpr mutation [36, 37]. This recessive mutation,
located on chromosome 1, caused a single amino acid
change (Leu > Phe) which prevented FasL from binding to
its receptor. Therefore, a deﬁciency in Fas signaling results
in an SLE-like phenotype due to defective Fas-mediated
apoptosis. In humans, defective Fas signaling can lead to the
development of autoimmune lymphoproliferative syndrome
(ALPS)whichshares manysymptoms with SLEalthoughGN
is uncommon in ALPS patients [38].
The SLE symptoms attributed to Fas deﬁciency in
MRL/lpr mice are dependent on both CD4+ T-cells and
B-cells as their absence decreased autoimmunity [39, 40].
FurtherstudiesonFas-deﬁcientT-cellsusingthe(C57BL/6×
MRL)F1 autoimmune strain resulted in lymphopenia as
activated T-cells upregulated FasL, promoting the apoptosis
of peripheral lymphocytes [41]. Meanwhile, in the presence
of the lpr mutation, the nonautoimmune C3H/HeJ and
C57BL/6J strains developed lymphoproliferation and had a
reduced lifespan [42]. In addition, high levels of IgM and
IgG antibodies, in particular autoantibodies against DNA
and IgG, were detected in these strains. Conditional deletion
of Fas in T-cells, B-cells, or both T-cells and B-cells in
nonautoimmune C57BL/6 mice resulted in higher levels of
autoantibodies but lymphoproliferation was not observed.
To reconstitute the phenotype seen in lpr mice, Fas deletion
had to be present in both lymphoid and nonlymphoid cells
[41]. In particular, Fas deﬁciency in dendritic cells (DCs)
led to systemic autoimmunity as it induced elevated ANA,
splenomegaly, and accumulation of mature DCs [43].
2.2.3. Eﬀect of the MRL Genetic Background in Disease
Development. Expression of the lpr mutation in either the
C3H/HeJ and C57BL/6J strains did not result in nephritis
[44]. In contrast, Fas-suﬃcient, MRL+/+ mice displayed the
pathological eﬀects of nephritis though onset of symptoms
was signiﬁcantly delayed when compared to MRL/lpr mice.
Therefore, the MRL background genes play an important
role in the development of disease. Characterization of
(MRL-Faslpr × C57BL/6-Faslpr)F2 mice revealed four sus-
ceptibility loci, Lmb1–Lmb4, that were linked to anti-dsDNA
autoantibodies and glomerulonephritis [45]. In particular,
studies on congenic mice showed that Lmb3, located on the
telomeric region of chromosome 7, had a signiﬁcant eﬀect
on lymphoproliferation and enhanced T-cell proliferation
while T-cell apoptosis was reduced [46]. Recently, a single
nonsense mutation (C > T) in the Coronin-1A gene, located
within the Lmb3 susceptibility locus, was identiﬁed in the
Scripp substrain of C57BL/6 and it resulted in suppression
of disease when crossed to MRL/lpr [47]. Coronin-1A binds
F-actin and prevents its assembly and depolymerization.
Nonfunctional Coronin-1A, from the mutant Lmb3 locus,
was associated with increased T-cell apoptosis and reduced
T-cell activation and proliferation. Further characterization4 Journal of Biomedicine and Biotechnology
of the MRL background should reveal additional candidate
genes that promote autoimmunity in MRL/lpr mice.
2.3. BXSB/Yaa
2.3.1. Derivation and Phenotype of the BXSB/Yaa Strain.
Lymphoproliferation was observed in males of an (C57BL6/J
× SB/Le)F1 intercross and its backcross to SB/Le. A recom-
binant inbred strain, BXSB/Mp, was derived from this
backcross, and nearly 100% of BXSB mice develop a lupus-
like disease that was much more severe with earlier onset in
males [48, 49]. The disease phenotypes include secondary
lymphoid tissue hyperplasia, immune complex-mediated
GN, monocytosis, hypergammaglobulinemia, antinuclear
and antierythrocytic autoantibodies, and high-serum retro-
viral glycoprotein gp70 titers [48, 50]. Mean survival is
roughly 5 months in males and 14 months in females, and
the major cause of death is proliferative GN [48, 50].
2.3.2. Eﬀect of the Y Chromosome in Disease Development.
The fact that disease is greatly accelerated in BXSB males
suggested the presence of a susceptibility element on the Y
chromosome or that sex hormones play a role in this model.
Orchiectomy did not delay onset or severity in BXSB males,
while ovariectomy did not exacerbate disease in females, rul-
ing out a hormonal eﬀect [51]. Moreover, consomic studies
showed that the BXSB-derived Y chromosome exacerbated
disease when combined with either NZW or MRL genetic
backgrounds [52, 53] .T h u s ,a ne l e m e n t ,t e r m e dY - l i n k e d
autoimmuneaccelerator(Yaa),wasdeemedtoberesponsible
for the acute disease in BXSB males.
It is now known that Yaa is due to a translocation of the
telomeric end of the X chromosome to the Y chromosome,
resulting in the duplication of at least 16 genes and a ∼2-
fold expression in many of these genes [54, 55]. Among
these is Toll-like Receptor 7 (Tlr7), which encodes an innate
pattern recognition receptor found in B cells and antigen
presentingcells(APCs).TLR7isactivatedbyviralssRNAand
signalsthrough themyeloiddiﬀerentiationprimary response
gene 88 (MyD88) adaptor resulting in nuclear factor NF-
κβ activation and expression of type I IFN (IFN I) and
other proinﬂammatory cytokines [56]. Importantly, it has
been shown that TLR signaling can act as signal 2 in B
cell activation and that those interactions with endogenous
RNA ligands are suﬃcient for autoreactive B cell activation
[57, 58]. Additionally, disease activity is extremely sensitive
to TLR7 expression. Where a 2-fold increase by the Yaa
translocation only results in overt disease in the presences
of other susceptibility alleles, greater increases in expression
result in a Tlr7 dose-responsive disease that does not require
other lupus susceptibility loci [59]. Moreover, deletion of
the endogenous copy of Tlr7 from the X chromosome
abrogates Yaa-induced monocytosis, lymphoid activation,
splenomegaly, GN, and mortality [59–61]. Thus, Tlr7 gene
duplication has been deemed to be the major functional
contributor to the Yaa phenotype. Shen et al. have recently
reported a human allele of the TLR7 gene with associated
risk for SLE development in males [62]. This human
susceptibility allele increased the expression of TLR7 and of
IFN I-regulated genes in blood monocytes. In this way, TLR7
dose increases lupussusceptibility in both mice and humans.
It is also likely that there is a minor contribution
from other genes in the translocated Yaa interval, since
endogenousTlr7 deletion doesnot eliminate all Yaa-induced
phenotypes. Lupus prone Yaa+·Tlr7− mice still display some
humoral abnormalities, increased autoantibody production,
and a decreased marginal zone (MZ) B cell compartment as
compared to lupus prone Yaa−·Tlr7+ mice [60, 61].
2.3.3. Eﬀect of the BSXB GeneticBackground in Disease Devel-
opment. While the Yaa allele is certainly the most distin-
guishable feature of the BSXB model, it is not the whole
story. Infact, theYaa mutationaloneisnotsuﬃcienttocause
disease. This is clearly illustrated by the fact that nonlupus
prone strains, such as B6 and CBA, that are consomic for
the BSXB Y chromosome do not develop disease [52, 63].
The BXSB MHC (H-2b/b) locus plays a dominant role in
disease activity since congenic BSXB.H-2d/d mice have a less
severe syndrome, while BSXB.H-2b/d and BSXB.H-2b/b mice
have the full disease [64]. However, as stated above, B6·Yaa
(H-2b/b) mice have no malady. Therefore, there are non-
MHC-linked autosomal elements in the BSXB genome that
contribute to disease development.
Quantitative trait linkage analyses have identiﬁed BXSB
susceptibilityloci on chromosomes 1,3, and 13(Bxs1-6)[ 65,
66]. These loci are all derived from the parental SB/Le strain
except for Bxs5 on chromosome 3, which is a transgressive
allele derived from B10 [49]. Bxs1-4 are all located on
chromosome 1 and studies using congenic mice conﬁrmed
that these loci confer lupus phenotypes [67]. Interestingly,
Bsx3 overlaps with Sle1 and seems to have the most robust
eﬀect. This suggests that like Sle1, Bsx3 may itself contain
multiple susceptibility loci, some of which might be allelic.
Of the four loci located on chromosome 1, only Bsx2 has
a proposed candidate gene. RNA and protein levels of the
innate scavenger receptor Marco (macrophage receptor with
collagenous structure) are reduced in the macrophages of
Bxs2-containing congenic mice. This leads to a defect in
clearance of apoptotic material, which is generally associated
with the development of systemic autoimmunity [68].
Bxs6 on chromosome 13 is linked to increased serum
gp70 and anti-gp70 autoantibody. The presence of Yaa
greatlyenhancesBxs6 resultinginnephritisduetodeposition
of the associated gp70 immune complexes (gp70IC) in
glomeruli. Gp70 is a glycoprotein subunit encoded by the
viral envelope env gene of endogenous retroviruses that is
produced by hepatocytes as an acute phase protein [69].
Though not proven conclusively, there is a good deal of
evidence for a role of endogenous retroviruses in lupus
pathogenesis (reviewed in [70]). Bsx6 overlaps with two
other loci, NZW-derived Sgp3 [71] and 129-derived Gv1
[72], which are also involved in the regulation of serum gp70
levels. This positional and functional relationship between
these three loci suggests that they may be caused by the same
gene(s). Further, TLR7 activation causes Sgp3-mediated
upregulation of serum gp70, in much the same way that
Yaa enhances of Bxs6-mediated upregulation of serum gp70
[73]. Sgp3 has been the most extensively analyzed and hasJournal of Biomedicine and Biotechnology 5
been recently narrowed down to a 5.42Mb region in which
21 of the 30 genes encode Kr¨ uppel-associated box zinc-
ﬁnger proteins (KRAB-ZFP) that are capable of suppressing
proviral transcription through the heterochromatization
viral integration sites [70]. KRAB-ZFPs are, therefore, the
primary candidate genes for Sgp3 and likely for Bxs6.
3.InducedModelsofLupus
3.1. The Pristane-Induced Lupus Model. Unlike the mouse
models mentioned above, in which genetic factors play
the major role, induced mouse models develop lupus after
exposure to certain environmental triggers. Intraperitoneal
injections of pristane (2, 6, 10, and 14 tetramethylpen-
tadecane, TMPD), an isoprenoid alkane found at high
concentration in mineral oil, is a standard method to obtain
ascitic ﬂuid enriched in monoclonal antibodies. However,
pristane administration in BALB/c mice induces autoanti-
bodies characteristic of lupus, such as antiribonucleoprotein
(RNP)antibodies (anti-Su, anti-Sm,and anti-U1RNP),anti-
DNA, and anti-histone, to a level comparable to that found
in MRL/lpr mice [74, 75]. Pristane-treated mice also have
immune-complex deposition in the kidney leading to severe
proteinuria and nephritis [75]. Besides the BALB/c strain,
almost all mouse strains are susceptible, to a variable extent,
to the pristane-induced production of antibody and lupus
manifestations [76], conﬁrming that environment has a
considerable importance in lupus. Like human SLE patients
and NZB/WF1 model,pristine-induced lupusismore severe
in females than in males, at least in SJL/J strain [77].
3.1.1. Cytokines in Pristane-Induced Lupus. Inﬂammatory
cytokines have critical eﬀects in pristane-induced lupus.
By using BALB/c IL-6−/− mice, it was found that anti-
ssDNA, dsDNA, and chromatin antibodies are highly IL-
6-dependent whereas anti-RNP/Sm and anti-Su antibodies
have no obvious correlation with IL-6 levels [78]. Interest-
ingly, anti-dsDNA antibodies generally develop after renal
disease, which indicates that these autoantibodies do not
participate in the development of nephritis in this model.
When pristane was administered to lupus-prone NZB/W
F1 mice, it greatly accelerated the disease and lead to
large amounts of IL-12, anti-Sm, anti-Su, and anti-RNP
autoantibody production, implying a linkbetween IL-12 and
these anti-RNP autoantibodies [79]. This was conﬁrmed by
thefact that IL-12 deﬁciencypreventedpristane-treated mice
from anti-RNP/Su IgG production and nephritis [80]. These
studies revealed that the production of diﬀerent autoan-
tibodies may be induced by diﬀerent cytokine pathways
and contribute diﬀerently to end-organ disease. In another
study, IFN-γ deﬁciency signiﬁcantly protected pristane-
treated BALB/c mice from autoantibody production and
renaldiseasewhereasIL-4deﬁciencyhasnoeﬀect[81].Thus,
pristane-induced lupus may be attributable to a shift of the
T-helper cell subsets, Th1-Th2, balance.
Overexpression ofIFN-Iand interferon-stimulated genes
(ISGs, also called “interferon signature”) has been closely
associated with ANA production and disease severity in SLE
patients [82]. Pristane-induced lupus is the only animal
model that shows an interferon signature. Indeed, studies
in pristane-induced lupus have revealed that IFN-I receptor
deﬁciency (IFNAR−/− or IFNAR2−/−) completely erased
the interferon signature, eliminated anti-RNP, anti-Sm, and
anti-dsDNA autoantibodies, reduced anti-ssDNA and anti-
histone IgG, and signiﬁcantly improved GN [83, 84]. IFN-
I may contribute to autoantibody production by regulating
TLR7/9 expression and activation in B cells [84]. IFN-I also
seems to regulate another autoantibody mediator, IL-12, as
IFNAR−/− mice fail to elevate IL-12 level following pristane
treatment [83].
Instead of plasmacytoid dendritic cells (pDCs) which
have been identiﬁed as the major producers of IFN-I in
human lupus [85], an accumulation of peritoneal immature
Ly6Chigh monocytes is the major source of IFN-I in pristane-
treated mice. Depletion of this cell population rapidly
abolished the interferon signature and autoantibody produc-
tion in pristane-treated mice [86] .I F N - Ii nt u r nm e d i a t e s
the recruitment of Ly6Chigh immature monocytes to the
peritoneum through the upregulationof chemokines such as
CCL2, CCL7, and CCL12. IFN-1 also prevents the matura-
tion of monocytes, with a twofold eﬀect: ﬁrstly, immature
monocytes are a major source of IFN-I. Therefore, blocking
of monocyte maturation results in a vicious feedback loop
of IFN-1 production, monocyte recruitment, and block in
an immature state.Secondly,failure ofmonocyte maturation
into phagocytic Ly6Clow monocytes/macrophages leads to
an impaired clearance of cell debris, which is an important
stimulus of inﬂammation and autoantibody production
[87]. Thus, IFN-I production by Ly6Chigh monocytes may be
a major cause of chronic inﬂammation and SLE.
Pristane induces IFN-I production exclusively through
the TLR7/MyD88 pathway [88]. TLR7 deﬁciency not only
abolishes pristane-induced IFN-I production but also elimi-
nates autoantibody production and renal disease, indicating
a key role of TLR7/MyD88/IFN-I pathway in this model [88,
89]. FcγR recognizes the Fc portion of extracellular IgG and
is proposed to mediate the intake of immune complex that
subsequently activates endosomal TRLs, such as TLR7 [90].
However, IFN-I and autoantibody production are FcγR-
independent in pristane-induced lupus [88]. Therefore, the
modulation of TLR7 by pristane does not rely on immune
complexes.Theexact mechanism ofpristane-mediated TLR7
activation remains to be identiﬁed.
3.1.2. Other Manifestations of Pristane-Induced Lupus. In
addition to nephritis, hemorrhagic pulmonary capillaritis
and arthritis have also been identiﬁed in pristane-treated
mice [91]. 14 days after a single dose of pristane injection,
bronchoalveolar lavage (BAL) ﬂuid becomes hemorrhagic
with elevated neutrophil counts and high levels of IL-6 and
IL-10. Perivascular inﬁltrates of immune cells and endothe-
lial injury are also found in the lung of pristine-treated mice
[91]. Some SLE patients also develop pulmonary capillaritis
[92],andwhetherpristane-inducedhemorrhagic pulmonary
capillaritis can serve as a valid model for human lupus lung
disease remains to be veriﬁed. The arthritis symptoms in6 Journal of Biomedicine and Biotechnology
pristane-induced lupus include synovial hyperplasia, perios-
titis, and progressive marginal erosions [93, 94]. Pristane-
induced arthritis is tumor necrosis factor (TNF) α mediated,
as treatment with neutralizing anti-TNF-α antibody amelio-
rates the arthritis symptoms [95]. The broader extension of
end-organ targets as well as the preeminent role plays by IFN
I make pristane-induced lupus arguably a model of choice
for mechanistic studies of human lupus.
3.2. Induced Chronic Graft-versus-Host Disease
3.2.1. Highlights and Advantages of the Parent into F1 Meth-
od. Various models of induced graft-versus-host disease
(GVHD) have been used as models of lupus. As with the
pristane-induced model, these models require only a single
injection ofdonorcells toinduce a lupus-likesyndrome. The
disease process is reproducible, with severity correlating to
the number of allografted cells. Because this method induces
a rapid disease onset from a known starting point, the study
of lupus induction is greatly facilitated as compared to the
spontaneousmodelsoflupus.Asanexample, autoantibodies
are detectable as early as 10–14 days after induction in these
models whereas it can be several weeks to months after
birth for the same phenotype to develop in spontaneous
lupus models. Further, since the donor T cells undergo
activation and expansion, they are relatively easy to observe
by ﬂow cytometry, allowing the study of the eﬀect of various
modiﬁcations on the donor as well as the host cells.
In the parent into F1 (P → F1) model, lymphocytes are
transferred intoa semiallogenicrecipientsuch thatthedonor
cells react to the host, and the host is tolerant to the donor
allograft. (reviewed in [96]). Depending on the model used,
an acute or a chronic GVHD (aGVHD or cGVHD) ensues.
In most models of P → F1, such as B6 into (B6 × DBA)F1,
aGVHD is induced by donor CD8+ T cells, which manifests
as severe lymphopenia of host cells as well as strain-speciﬁc
connective tissue diseases. Host B cells are most sensitive
to this CTL killing and may be almost completely ablated
after 2 weeks, followed by host APCs, then CD4+ T cells,
and ﬁnally host CD8+ T cells. Conversely, DBA into (B6 ×
DBA)F1 (DBA → BDF1) results in cGVHD, a donor CD4+-
mediated response resulting in massive host polyclonal B
cell activation, expansion, and immunoglobulin production.
This chronic condition exhibits several similarities to SLE,
including ANA, lupus-speciﬁc autoantibodies, and immune
complex-mediated GN. Another feature of DBA → BDF1
is that the lupus pathogenesis in this model is more severe
in females than males allowing the study of gender-biased
lupus etiology [97, 98]. Additionally, DBA → BDF1 allows
for identiﬁcation of CTL-promoting treatments in vivo,s u c h
as with agonist anti-CD40 antibody, IL12, and antagonist
anti-CD80 antibody [99–101].
The induction of a cGVHD instead of aGVDH response
is caused by a diminished capacity for DBA CD8+ T cells to
produce a CTL response to the F1 host. Correspondingly, B6
into (B6 × DBA)F1 will result in cGVHD if the donor cells
are depleted of CD8+ T cells. The ensuing lupus phenotypes
include ANA, anti-dsDNA and anti-RBC autoantibodies,
and GN. The major advantage of B6(-CD8) → F1 over the
DBA → BDF1 model is that genetic modiﬁcation of the do-
nor cells can be examined due to the plethora of knockout
and transgenic B6 mice. To this extent, this model has
demonstrated that partial CTL deﬁciency due to the lack of
perforin (B6·Pfp−/− → F1) or Fas/FasL (B6·gld → F1) was
suﬃcient to induce a CD4+-mediated cGVHD phenotype.
B6(-CD8) → F 1w a sa l s ou s e da sac o m p l e m e n to f
B6 → F1 (not depleted of CD8+ T cells) to study in vivo
mechanisms that mediate the overall donor CD8+ Tc e l l
versus CD4+ T cell response, and thus result in aGVHD
versus cGVHD. One such study demonstrated that TNFα
blockade inhibited the early induction of CTLs and skewed
Tc e l lc y t o k i n ep r o ﬁ l et oa n t i b o d yp r o m o t i n gI L - 4 ,I L - 6 ,a n d
IL-10, resulting in an antibody mediated cGVHD response
[102]. This novel ﬁnding revealed the potential of TNFα-
blocking treatments to instigate humoral autoimmunity.
Another study described a positive role in B6(-CD8) →
F1 cGVHD and a negative role in B6 → F1 aGVHD for
the TNF family member, TRAIL, highlighting its role in the
promotion of lupus [103].
3.2.2.B6·H-2bm12 ←→B6cGVHD. When B6·H-2bm12 lym-
phocytes, whose MHC II locus confers a 3 amino acid
substitution in H-2b, are transferred into B6 hosts with
the wild-type H-2b locus, cGVHD develops. The lupus-
like phenotypes in this model include ANA, anti-dsDNA,
antichromatin, and anti-Sm autoantibodies, and GN [104].
Since the MHC disparity between donor and host is limited
t oc l a s sI Ii nt h i sm o d e l ,C D 8 + T cell depletion of donor
lymphocytes is not required. Also, since this model works
equally well with B6·H-2bm12 → B6 and B6 → B6·H-2bm12,
donor and host gene modiﬁcations can be examined by the
use of knockout and transgenic mice.
Although cGVHD has been shown to be mediated
through donor CD4+ T cells and host B cells, an inter-
esting facet of cGVHD was revealed using this model.
The observation that a response did not occur in CD4−/−
hosts indicated a role for endogenous CD4+ T cells [189].
Further, B cells raised in such an environment had intrinsic
defects in their ability to produce an alloresponse [190]. It
has been recently reported that B cells require “nurturing”
during early ontogeny in the form of IL-4 [191]. In lieu
of endogenous CD4+ T cell nurturing, large doses of rIL-4
or agonist anti-CD40 antibody in CD4−/− hosts during this
critical developmental period were also suﬃcient for B cells
to develop with alloreactive potential.
4.TherapeuticStudiesforSLEonMouseModels
Mouse models of SLE have been used not only to dissect
disease mechanisms but also to test potential therapies.
In addition to validating targets, testing drugs on mouse
models of SLE has proved indispensable before they go to
clinical trials. We have summarized the major therapeutic
studies that have been conducted on mice models of SLE
in Table 1. Several components of the immune system,
such as cytokines, B-cells, T-cells, and hormones have been
identiﬁed as potential targets for therapy, which have beenJournal of Biomedicine and Biotechnology 7
Table 1: Summary of treatments tested in mouse models of lupus, their targets, proposed mechanisms, outcomes in the mouse, and follow
up in clinical trials.
Targets Treatment Mouse model Mechanisms Main outcomes Ref Clinical trial
Targeting cytokines
IL-6
IL-6R mAb MRL/lpr Nephritis↓,a n t i - d s D N A
Ab↓ [105] Tocilizumab∗
IL-6R mAb NZB/W F1 Inhibits IgG class
switch
Survival↑,I g GA N A ↓,
proteinuria↓ [107]
A Phase I trial showed
both decreased disease
activity and side eﬀects
[106]
IL-6 mAb NZB/W F1
Suppresses
autoreactive B cell
and T cell
Nephritis↓,a n t i - d s D N A
Ab↓ [108]
IL-10
IL-10 inhibitor
(AS101) NZB/W F1 Decreases IL-10,
increases TNF-α
Delayed onset,
anti-DNA Ab↓,
proteinuria↓, glomerular
deposition↓
[109]
Antagonizing anti- IL-10
mAb
A small-scaletrial
showed eﬃcacy. [110]
IL-10 mAb NZB/W F1 Neutralizes IL-10,
increases TNF-α
Delayed onset, survival↑,
ANA↓ [111]
rIL-10 MRL/lpr Suppresses Th1
response IgG2a anti-dsDNA↓ [112]
AAV-IL-10 (low
exp.)
B6·Sle1·Sle2·S
le3
Suppresses Th1
response
ANA↓,G N ↓,Tc e l l
activation↓ [113]
TNF-α rTNF-α NZB/W F1 Decreases cellular
response Delayed onset, survival↑ [114]
Inﬂiximab
A small-scaletrial
showed both eﬃcacy
and side eﬀects [115]
Etanercept
Phase II trial for discoid
lupus in progress
IFN-α IFN-α kinoid
vaccination NZB/W F1 Induces anti IFN-α
neutralizing Ab
Delayed onset, survival↑,
proteinuria↓ [116]
MEDI-545
(sifalimumab)
Phase I trial showed
positive result [117]
rhuMab IFN-α
(Rontalizumab)
Phase I trial showed
positive result [118]
IFN-β IFN-β MRL/lpr
Reduces both cellular
and humoral
responses and
cytokine production
Survival↑, proteinuria↓,
skin lesions↓,A N A ↓,
splenomegaly↓
[119]
IFN-γ IFN-γ cDNA
vaccination MRL/lpr Induces anti IFN-γ
neutralizing Ab
Survival↑,l y m p h o i d
hyperplasia↓,A N A ↓,
GN↓
[120] AMG 811
Phase I trial in progress
IFN-γ mAb NZB/W F1 Survival↑, proteinuria↓,
anti-DNA Ab↓ [121]
IL-17 Rock2 inhibitor
(Fasudil) MRL/lpr
Inhibits IRF4
phosphorylation and
reduces IL-17 and
IL-21 production
Anti-dsDNA Ab↓,
glomerular deposition↓,
proteinuria↓
[122]
IL-21 IL-21R·Fc MRL/lpr
Decreases T cell
numbers and alters B
cell functions
Total Ig ↓,a n t i - d s D N A
Ab↓, proteinuria↓ skin
lesions↓,
lymphadenopathy↓
[123]
IL-18 IL-18 cDNA
vaccination MRL/lpr Induces anti-IL-18
neutralizing Ab Survival↑,G N ↓,I F N -γ↓ [124]8 Journal of Biomedicine and Biotechnology
Table 1: Continued.
Targets Treatment Mouse model Mechanisms Main outcomes Ref Clinical trial
BAFF Adenovirus-
BAFF-R-Ig NZM2410
Depletes B cell,
decreases T cell
activation and
myeloproliferation
Survival↑, proteinuria↓,
splenomegaly↓,r e v e r s e s
disease
[125] Belimumab
Anti-BAFF-Ig B6·lyn−/− Nephritis↓, [129]
Phase III met primary
complex end point.
[126, 127].
BAFF and April Human TACI-Ig NZB/WF1 Blocks BAFF and
April signaling
Survival↑, proteinuria↓,
no signiﬁcantchange in
anti-dsDNA Ab level
[130]
Atacicept
Phase II terminated
[128]
Adenovirus-
TACI-Ig (w/ or
w/o CTLA4-Ig
co-
administration)
NZB/W F1
Blocks BAFF and
April signalingsplenic
B cell depletion
Survival↑, delayed
onset,, ANA↓,
proteinuria↓, nephritis↓,
reverses disease only
when CTLA4-Ig
coadministered
[131]
Adenovirus-
TACI-Fc
MRL/lpr,
NZB/W F1,
Blocks BAFF and
April signaling
In MRL/lpr: survival↑,
GN↓, proteinuria↓,In
NZB/W F1: anti-TACI
antibodies neutralized
TACI-Fc
[132]
Adenovirus-
TACI-Ig NZM2410 Blocks on BAFF and
April signaling;
Survival↑, proteinuria↓,
splenomegaly↓,r e v e r s e s
disease
[125]
B cell depletion
CD20 Anti-CD20 mAb MRL/lpr ADCC, CDC
Serum Ab and ANA↓,
nephritis↓, proteinuria↓,
dermatitis↓
[133]
Rituximab
Failed to reach primary
end point [134, 135]
Anti-CD20 mAb NZB/W F1 ADCC, CDC
Treatment on
12–28-wk-old mice
ameliorates disease,
while treatment on 4-wk
old mice hastens disease
[137]
Ocrelizumab
Phase III terminated
[136]
CD22 Anti-CD22 mAb NZB/W F1 ADCC, targets
inhibitory receptor
Able to deplete several B
cell subsets. No
signiﬁcant eﬀect on
improving survival
[137]
Epratuzumab
Phase IIb trial showed
positive result [138, 139]
CD79
Anti-CD79 α and
Anti-CD79 β
mAb
MRL/lpr
Survival↑,I g G
antichromatin↓,s k i n
lesions↓ Inﬂammatory
inﬁltrates↓
[140]
Proteasome
Proteasome
inhibitor
bortezomib
NZB/W F1 and
MRL/lpr
Eliminates both
short-lived and
long-lived plasma
cells
Survival↑,A N A ↓,G N ↓ [141]
Targeting T cell-APC interactions
CTLA4-Ig NZB/W F1 Inhibits B7-CD28
interaction Survival↑,A N A ↓ [142,
143]
Abatacept
The ACCESS trial is in
progress [144]Journal of Biomedicine and Biotechnology 9
Table 1: Continued.
Targets Treatment Mouse model Mechanisms Main outcomes Ref Clinical trial
Adenovirus-
CTLA4-Ig NZB/W F1 Inhibits B7-CD28
interaction Survival↑,A N A ↓,G N ↓ [145]
CD28-B7 CTLA4-Ig
transgene B6 lyn−/− Inhibits B7-CD28
interaction
Myeloid hyperplasia↓,
splenomegaly↓ IgG
ANA↓, renal disease
unaﬀected
[146]
CTLA4-Ig and
anti-gp39 NZB/W F1
Simultaneously
inhibits B7-CD28 and
CD40/gp39
interaction
Survival↑,A N A ↓,G N ↓,
eﬀects are more
signiﬁcant than
CTLA4-Ig alone
[143]
Targeting T follicular helper cells
CD3 Nasal anti-CD3
Ab NZB/W F1
Downregulates the
expression of IL17
and IL21 by Tfh cells
ANA↓,G N ↓ [147]
ICOS-B7RP-1 anti-B7RP-1 Ab NZB/W F1
Downregulates ICOS
and reduces Tfh cell
number
Survival↓,a n t i - d s D N A
Ab↓, proteinuria↓ [148]
Targeting other receptors
FcgRIIB
FcgRIIB
expressing
retrovirus
NZM2410,
BXSB,
B6Fcgr2b−/−
Restores FcgRIIB level
ANA↓,i m m u n ec o m p l e x
deposition↓,
proteinuria↓,G N ↓,l u n g
pathology↓
[149]
TLR7/TLR9
Immunoregula-
tory sequence
(IRS) 954
NZB/W F1 Reduces the
production of IFN-α
Survival↑,A N A ↓,
proteinuria↓,G N ↓, [150]
Programmed
death-1 (PD-1)
Neutralizing
PD-1Ab NZB/W F1 Promotes suppressive
CD8+ T cells
Survival↑, delayed
nephritis, IgG↓,
anti-dsDNA IgG↓
[151]
Targeting cell signaling
Syk
Syk inhibitor
R788 NZB/W F1
Blocks B cell receptor
(BCR) and FcR
signaling
Survival↑, proteinuria↓,
renal disease↓ [152]
Syk inhibitor
R788
MRL/lpr or
BAK/BAX−/−
Blocks BCR and FcR
signaling
Skin lesions↓
lymphadenopathy and
splenomegaly↓,r e n a l
disease↓
[153]
PI3K γ AS605240
compound MRL/lpr Reduces T and B cell
activation
Survival↑,r e n a l
inﬁltrates↓,G N ↓ [154]
mTOR Rapamycin NZB/W F1 Immunosuppression
Survival↑,a n t i - d s D N A
Ab↓, splenomegaly↓,
albuminuria↓
[155]
Rapamycin
A small scale trial
showed eﬃcacy [156]
Cellular therapies
Regulatory B cells
(Breg)
Anti-CD40
injection MRL/lpr Agonistic anti-CD40
expands Breg
Survival↑,a n t i - d s D N A
Ab↓, proteinuria↓,s k i n
lesions↓
[157]
Regulatory T cells
(Treg)
Adoptive transfer
of ex vivo
expanded Treg
NZB/W F1 T cell suppression
Survival↑,r e n a lI C
deposition↓,
proteinuria↓,G N ↓
[158,
159]
Umbilical cord
mesenchymal stem
cells (MSC)
MRL/lpr
immunosuppressive
and
anti-inﬂammatory
properties
anti-dsDNA Ab↓,
Proteinuria↓,r e n a l
disease↓
[160]
A small-scaletrial
showed positive result
[161]
Umbilical cord
mesenchymal stem
cells (MSC)
NZB/W F1
immunosuppressive
and
anti-inﬂammatory
properties
Survival↑,a n t i - d s D N A
Ab↓, proteinuria↓,r e n a l
disease↓
[162]10 Journal of Biomedicine and Biotechnology
Table 1: Continued.
Targets Treatment Mouse model Mechanisms Main outcomes Ref Clinical trial
Bone marrow
derived mese-
nchymal stem cell
(BM-MSC)
NZB/W F1
Inhibition of B cell
proliferation and
diﬀerentiation
dependent on IFN-γ
Glomerular IC
deposition↓,
lymphocytic
inﬁltration↓, glomerular
proliferation↓,
anti-dsDNA Ab and
proteinuria unaﬀected
[163]
Sex hormonemodulation
Estrogen Nafoxidine NZB/W F1 Delayed onset, survival↑,
ANA↓, proteinuria↓ [164]
Tamoxifen
A small-scaletrial
showed no eﬀect [165]
Estrogen Tamoxifen NZB/W F1 Reduces IgG3 ANA
production
Survival↑,I g G 3A N A ↓,
proteinuria↓,
thrombocytopenia↓,
glomerular deposits↓
[166,
167]
Fulvestrant (estrogen
receptor downregulator)
A small-scaletrial
showed some eﬃcacy
[168]
Estrogen Raloxifene NZB/W F1 Inhibits B cell
function
Anti-DNA Ab↓,k i d n e y
damage↓ [169]
Estrogen Indole-3-carbinol NZB/W F1 Blocks B cell and T
cell diﬀerentiation
Survival↑,A N A ↓,
nephritis↓ [170]
Androgen
Androgen
treatment on
castrated female
NZB/W F1 Unspeciﬁed Survival↑,I g GA N A ↓ [171] Dehydroepiandrosterone
Little clinical eﬀect [172]
Androgen Androgen
treatment
NZB/W F1,
MRL/lpr Unspeciﬁed Survival↑,a n t i - D N A
Ab↓ [173]
Peptide-based immunotherapy
Laminin Laminin derived
peptides MRL/lpr
Laminin derived
peptides
competitively bind
with ANA and
prevent their
deposition in the
kidney
Survival↑, proteinuria↓,
GN↓ [174]
HSC chaperone
protein
U1-70K snRNP
derived peptide
administered in
saline (P140)
MRL/lpr Impairs autoimmune
T cell response
Survival↑, proteinuria↓,
anti-dsDNA Ab↓
[175,
176]
P140
Ap h a s eI I as t u d y
showed positive result
[177]
Autoreactive B
and T cells
Histone peptide
H2B10−33,
H416−39,H 4 71−94
(SWR/ NZB)F1 Impairs autoimmune
Ba n dTc e l l
Survival↑, proteinuria↓,
ANA↓ [178]
Suppressive CD8+
T cells
pCONS NZB/W F1
Promotes suppressive
CD8+ T cells by
regulating Foxp3 and
PD-1
Survival↑, nephritis↓,
ANA↓
[179–
181]
Unclear
CDR1 of human
anti-DNA Ab
(hCDR1)
NZB/W F1
Modulation of
cytokines, regulatory
T cells and T cell
apoptosis
ANA↓, nephritis↓,C N S
symptoms↓ [182]
hCDR1
A small-scaletrial
showed positive result
[182]
Other therapies
Histone
deacetylase
Histone
deacetylase
inhibitors TSA
and SAHA
MRL/lpr
Decreases
transcription of key
cytokines involved in
SLE
Splenomegaly↓,
proteinuria↓,r e n a l
disease↓
[183]Journal of Biomedicine and Biotechnology 11
Table 1: Continued.
Targets Treatment Mouse model Mechanisms Main outcomes Ref Clinical trial
Topoisomerase I
Topoisomerase I
Inhibitor
irinotecan
NZB/W F1
Prevents anti-dsDNA
Ab from binding to
dsDNA
Survival↑, proteinuria↓
subendothelial immune
deposit↓
[184]
ACE ACE inhibitor
Captopril
NZB/W F1 and
MRL/lpr
Reduces TGF- β,I L - 4
and IL-10 production
Delayed onset,
proteinuria↓,r e n a l
lesion↓
[185]
HMG-CoA
reductase
HMG-CoA
reductase
inhibitor Statin
NZB/W F1
Immunomodulatory
eﬀects on B and T
cells and APCs
ANA↓, serum urea↓,
proteinuria↓, nephritis↓ [186]
ACE and
HMG-CoA
reductase
Coadministration
of Statin and ACE
inhibitor
Imidapril
MRL/lpr Synergistic eﬀect
Survival↑,A N A ↓,
proteinuria↓, glomerular
deposits↓,r e n a l
monocyte attractant
CCL2/MCP-1↓
[187]
CCL2/MCP-1 Spiegelmer
mNOX-E36 MRL/lpr
mNOX-E36 blocks
CCL2 without
induction of IFN-α
production
Survival↑, nephritis↓,
skin lesion↓,
peribronchial
inﬂammation↓
[188]
∗Drug names are shown in italic font.
tested in mouse models of lupus, most often in a preventive
rather than therapeutic mode. Some of the most successful
therapeutic approaches have lead to clinical trials, several of
which are currently in progress. Among them, Belimumab,
a humanized monoclonal antibody directed against B-cell
activating factor (BAFF), is the ﬁrst biologic treatment that
has met clinical trial end points and has been recommended
for SLE treatment. BAFF regulates the survival of B-cells.
It was determined that lupus-prone mice and SLE patients
have elevated levels of BAFF. Additionally, nonautoimmune
transgenic mice overexpressing BAFF showed lupus-like
symptoms [130]. Targeting BAFF receptors (BAFF-R, TACI,
or BCMA) in the NZM2410 and MRL/lpr lupus mouse
models was eﬀective in reducing disease symptoms [125,
132]. Murine studies targeting the BAFF pathway were
followed by clinical trials targeting BAFF in SLE patients.
The success of Belimumab in clinical trials is considered
a breakthrough in the search for new therapies for SLE
[126, 127]. This example serves to illustrate the important
role mouse models play in the development of eﬀective
treatments for this complex human disease.
A major limitation for drug trials in humans is that
although physiological parameters are collected, it is diﬃ-
cult to determine changes in internal organs, such as the
lymphoid organs and the kidneys. For example, the anti-
CD20 antibody (Rituximab) is able to deplete B cells in
humans through antibody-dependent cell-mediated cyto-
toxicity (ADCC) and complement-dependent cytotoxicity
(CDC) [192]. However, this data was mainly obtained from
human peripheral blood B cells, which represents only 2%
of the total B cells in the body [193]. Studies in mice have
shown that unlike the blood, the spleen, bone marrow, and
peritoneal cavity provide a reservoir for B cells in which
they are more resistant to drug depletion [133, 194, 195].
Therefore, depletion eﬃcacy seen in human blood does not
necessarily reﬂect a global depletion. This may be one of
the reasons why two randomized, double-blind, phase II/III
trials failed to show an eﬀect of Rituximab over placebo
in SLE patients [134, 135]. Moreover, drug eﬃcacy may
be diﬀerent between lupus-prone and lupus-resistant mice.
Anti-CD20 depletion of B cells has been shown to be much
more eﬃc i e n ti nB A L B / ct h a ni nM R L / l p rm i c e[ 133].
Therefore, it is crucial to test potential SLE therapies and
drugs directly in lupus-prone mice.
There are obvious limitations in evaluating lupus thera-
pies in mouse models. SLE targets the skin, joints, kidneys,
and many other organs in humans whereas mouse models
of SLE are characterized mainly by the development of
nephritis. This is probably due to the fact that the genetic
background is far more complicated in lupus patients than
in mouse models. Some lupus mice may develop lupus-like
symptoms other than renal disease, such as joint swelling
and skin rash in a portion of MRL/lpr mice, and pulmonary
symptoms in pristane-induced mice (see above). However,
no mouse model can mimic the complexity of human lupus.
Thus, drugs validated in mouse models may only be eﬀective
for a subset of symptoms or patients. To mimic the genetic
and pathological heterogeneity in humans, it is crucial to
use various mouse models in therapeutic studies. It has
been shown that same treatment can have variable eﬀects
on diﬀerent mouse models. For example, treatment with
a soluble form of the BAFF receptor (BAFF-R-Ig) induces
complete and enduring remission of established nephritis in
NZM2410 mice [125], while it is unable to reverse nephritis
in NZB/W F1 model unless a soluble form of cytotoxic T-
lymphocyteantigen4(CTLA4-Ig)iscoadministered toblock
Tc e l lc o a c t i v a t i o n[ 131]. This diﬀerence is probably due
to the fact that nephritic NZB/W F1 mice produce more
inﬂammatory mediators in the kidney than do nephritic
NZM2410 mice [125]. Thus, the genetic background should
be taken into account when testing therapies on mouse
models, and multiple models should be used to ensure12 Journal of Biomedicine and Biotechnology
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Figure 1: Integration of human and murine studies for new SLE drug discovery. Study of human SLE patients and mouse models of lupus
has led to the identiﬁcation of potential therapeutic targets. In-depth studies in murine models are undertaken to validate the association
of the potential targets with disease symptoms. The eﬃcacy of targeted treatments are ﬁrst tested on murine models of lupus prior to the
initiation of human clinical trials.
the applicability of drugs on the more complicated human
genetic background.
5.Summary
Murine models are useful tools for the study of the etiology
of lupus. A multitude of models exist, each sharing a subset
of attributeswith SLE observed in humans. In addition, each
model aﬀords the study of diﬀerent aspects of lupus patho-
genesis. For example, the cGVHD and pristane-induced
modelsallow forthe study of the mechanisms involved at the
onset of the disease, while the spontaneous models allow for
pr obin gofth egen eticca us esofdis ea s e.NZB/WF1a n dDB A
→ DBF1 can be used to study phenotypes in a gender-biased
context similar to that seen in humans. All models are valid
candidates for the study of therapeutic interventions.
To date, the use of murine models has identiﬁed sev-
eral novel candidate genes, and some of them have been
associated to SLE in humans. Further value in these models
is demonstrated by that fact that these genes were not
initially identiﬁed in human SLE studies. On the other
hand, recent genome-wide human studies have identiﬁed an
array of genes, many of which have no currently described
role in lupus. To this eﬀect, murine models allow for
forward genetics to identify novel genes that can then be
probed using a candidate gene approach to discover their
human susceptibility allele counterparts (Figure 1). Con-
versely, genes identiﬁed by human studies can be translated
to genetically modiﬁed murine models where their roles in
lupus pathogenesis can be followed in a forward genetics
manner. Both methodologies have proven their usefulness
and have the shared goal of identifying novel pathways and
targets for disease intervention.
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KRAB-ZFP: Kr¨ uppel-associated box zinc-ﬁnger
proteins
Marco: Macrophage receptor with
collagenous structure
MHC: Major histocompatibility complex
MyD88: Myeloid diﬀerentiation primary
response gene 88
MZ: Marginal zone
NF-κβ: Nuclear factor
kappa-light-chain-enhancer of
activated B cells
NZB/W F1: First generation oﬀspring from cross
between NZB and NZW
NZB: New Zealand black
NZM: New Zealand mixed
NZW: New Zealand white
Pbx1: Pre-B-cell leukemia transcription
factor 1
pDCs: Plasmacytoid dendritic cells
QTL: Quantitative trait loci
SLAM: Signaling lymphocytic activation
molecule
SLE: Systemic lupus erythematosus
SNP: Single nucleotide polymorphism
Th1: T helper 1
Th2: T helper 2
tlr7: Toll-like receptor 7
TMPD: Pristane (2, 6, 10, 14
tetramethylpentadecane)
TNF: Tumor necrosis factor
TNF-R: Tumor necrosis factor receptor
TRAIL: Tumor necrosis factor-related
apoptosis-inducing ligand
RBC: Red blood cell
Yaa: Y-linked autoimmune acceleration.
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